This is a single arm phase 2 trial evaluating the efficacy and tolerability of
intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer
patients with peritoneal metastasis and/or cancer cells on peritoneal cytology. Twenty
patients will be recruited into the study for an estimated period of two years. Paclitaxel
will be administered intraperitoneally at 40mg/m2 on Day 1 and 8 in patients receiving
standard intravenous oxaliplatin 130mg/m2 on Day 1 and capecitabine 1000mg/m2 on day 1-14.
The study hypothesizes that the addition of intraperitoneal paclitaxel with chemotherapy will
improve treatment efficacy.